2 PAM Autoinjectors
Closed Pre-Solicitation Posted
- Solicitation number
- 2-PAM-BARDA
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Not on record
- Place of performance
- Washington, District of Columbia, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Biomedical Advanced Research and Development Authority (BARDA), a component of the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, is conducting market research to procure 2-PAM (Pralidoxime) 600 mg autoinjectors designed for treating organophosphate and nerve agent poisonings. The agency seeks capabilities and technical information from businesses capable of developing emergency autoinjectors with specific requirements, including achieving FDA approval by the end of 2028 and meeting a 99.999% reliability standard by the end of 2027. Respondents must submit separate 10-page Business and Technical Representations electronically to kevin.dean1@hhs.gov by 4:00 P.M. ET on May 14, 2025. The technical representation must include comprehensive details about the product, including its intended indication, regulatory status, clinical development progress, manufacturing capacity, and shelf life information. This sources sought notice is strictly for market research purposes and does not obligate the government to award a contract or reimburse respondents for their information submission.
The pre-solicitation notice does not specify a specific set-aside designation and is open to both small and other than small businesses. The contract aims to support the CHEMPACK program, with a requirement to deliver 2,000,000 units in 500,000 incremental increments by September 30, 2032. While no specific award value or budget range is explicitly stated, the notice indicates a significant procurement scale for emergency medical autoinjectors. The solicitation is categorized under NAICS code 541714 for Research and Development in Biotechnology, suggesting a focus on advanced medical technology development. After reviewing submitted information, BARDA may publish a pre-solicitation synopsis on SAM.gov under Contract Opportunities, potentially leading to a formal solicitation for this critical medical countermeasure procurement.
Notice text
BARDA seeks pertinent marketplace data on availabilities and capabilities for procuring, stockpiling, and investing in the late-stage development of Pralidoxime (2-pyridine aldoxime methyl chloride; 2-PAM) autoinjectors for intramuscular injection. BARDA seeks information on availability, capabilities, and other pertinent marketplace data to support late-stage activities required for Food and Drug Administration (FDA) approval of 2-PAM (600 mg) autoinjectors.
Files
| File | Type | Posted |
|---|---|---|
| SSN 2-PAM BARDA Autoinjectors.pdf |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) | Office of the Assistant Secretary for Preparedness and Response | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity